Research outlook

Where immune thrombocytopenia treatment is heading

Immune thrombocytopenia · Updated Nov 14, 2026

Immune thrombocytopenia (ITP) is an autoimmune condition in which antibodies destroy platelets, causing bruising, bleeding and fatigue; roughly 3 in 100,000 adults are diagnosed each year in the US, and many children get a short-lived form. Steroids work at first but often wear off. Platelet-boosting pills and injections (thrombopoietin receptor agonists), rituximab and fostamatinib are used next. Newer drugs aim at the immune cells behind the disease: a BTK inhibitor was approved in 2025, and short-course antibodies against B cells and plasma cells are in phase 3.

  1. Now

    Nov 2026

    A BTK inhibitor pill approvedHappened 23% durable response

    Rilzabrutinib gave durable responses in 23% of heavily treated patients vs 0% with placebo; FDA approved August 2025.

    23%: durable platelet response, vs 0% with placebo.

    A short antibody courseHappened 54% free of treatment failure

    Four monthly doses of ianalumab kept 54% free of treatment failure at a year vs 30%.

    54%: free of treatment failure at 12 months (9 mg), vs 30%.

    Pills first for childrenHappened 65% sustained response

    Eltrombopag beat standard first treatment in children (65% vs 35% sustained response).

    65%: sustained platelet response, vs 35%.

  2. 6 months

    by May 2027

    Ianalumab at diagnosisLikely

    Novartis' VAYHIT1 (226 people), adding ianalumab to first-line steroids, finishes October 2026.

    Adding belimumab to rituximabPossible

    RITUX-PLUS 2 (132 people) finishes November 2026.

  3. 12 months

    by Nov 2027

    Ianalumab filingPossible

    Positive VAYHIT2 results could support an approval application for ianalumab.

    FcRn blockers retestedLong shot 13.7% response (subcutaneous)

    After the subcutaneous trial missed (13.7% vs 16.2%), argenx is testing intravenous efgartigimod in ADVANCE NEXT (due June 2028).

    13.7%: sustained platelet response, vs 16.2% with placebo.

  4. 3 years

    by late 2029

    Targeting plasma cellsPossible 91% platelet response

    Takeda's mezagitamab phase 3 (171 people) is due March 2028, after 91% responded at the top dose in phase 2.

    91%: platelet response at 600 mg, vs 23% with placebo.

    Another BTK inhibitorPossible

    Lilly's pirtobrutinib trial (68 people) is due February 2028.

  5. 5 years

    by late 2031

    Treating early to prevent chronic ITPPossible

    Amgen's ROMISTER adds romiplostim to steroids at diagnosis; due September 2029.

    CAR T cells for refractory ITPLong shot

    Off-the-shelf CAR T cells are in early testing for the hardest cases.

Happened Likely Possible Long shot

The research paths

Rising

B-cell and plasma-cell targeting

91% platelet response
Details and 5 trialsHide
Rising

BTK inhibitors

23% durable response
Details and 2 trialsHide

Oral drugs that reduce platelet destruction.

WatchPirtobrutinib; LUNA 4.

Mixed

Platelet boosters and antibody lowering

65% sustained response (children)
Details and 2 trialsHide

Borrowed from other conditions

From B-cell cancers

Rilzabrutinib and pirtobrutinib

Approved / Phase 2

BTK inhibitors, a class first developed for lymphoma and CLL.

From Multiple myeloma

Anti-CD38 antibodies

Phase 3

The same target as daratumumab, used to remove antibody-making plasma cells.

From Lupus

Belimumab

Phase 2/3

A BAFF blocker added to rituximab to prevent B cells returning.

Open to join now

See every recruiting ITP trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Ianalumab with first-line steroids (VAYHIT1)B-cell and plasma-cell targeting
Oct 2026
Belimumab plus rituximab (RITUX-PLUS 2)B-cell and plasma-cell targeting
Nov 2026
Nov 2027
Feb 2028
Mezagitamab vs placeboB-cell and plasma-cell targeting
Mar 2028
Intravenous efgartigimod (ADVANCE NEXT)Platelet boosters and antibody lowering
Jun 2028
Ianalumab with thrombopoietin agonistsB-cell and plasma-cell targeting
Jan 2029
Romiplostim plus steroids at diagnosis (ROMISTER)Platelet boosters and antibody lowering
Sep 2029
CTX112, an off-the-shelf CAR T cellB-cell and plasma-cell targeting
Dec 2033

What just happened

Subcutaneous efgartigimod misses goal

ADVANCE SC, Am J Hematol.

Ianalumab course delays treatment failure

VAYHIT2, NEJM.

Mezagitamab raises platelets in phase 2

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See ITP trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.